Baystate Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Baystate Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$101K	Hold	527	–	–	0.01%	273
2023 Q3	$93.3K	Hold	527	–	–	0.01%	262
2023 Q2	$100K	Hold	527	–	–	0.01%	256
2023 Q1	$106K	Hold	527	–	–	0.01%	244
2022 Q4	$125K	Hold	527	–	–	0.01%	231
2022 Q3	$105K	Hold	527	–	–	0.01%	228
2022 Q2	$77K	Hold	527	–	–	0.01%	266
2022 Q1	$86K	Sell	527 -528	-50%	-$80.4K	0.01%	259
2021 Q4	$179K	Hold	1,055	–	–	0.02%	188
2021 Q3	$199K	Hold	1,055	–	–	0.02%	151
2021 Q2	$179K	Hold	1,055	–	–	0.02%	153
2021 Q1	$149K	Buy	+1,055	New	+$159K	0.02%	154
2017 Q1	–	Sell	-460	Closed	-$19K	–	661
2016 Q4	$19K	Buy	+460	New	+$19.3K	﹤0.01%	234

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Baystate Wealth Management's ALNY Position: Q4 2023 in Review

Baystate Wealth Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q4 2023 at 527 shares worth $101K. The position accounts for 0.01% of the portfolio, ranked #273.

Baystate Wealth Management first reported a position in ALNY in Q4 2016 and has held it in 13 quarters since. The position peaked at $199K in Q3 2021. 499 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

Baystate Wealth Management held 527 shares of Alnylam Pharmaceuticals worth $101K as of Q4 2023.
Baystate Wealth Management left its Alnylam Pharmaceuticals share count unchanged in Q4 2023.
Alnylam Pharmaceuticals made up 0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #273 holding.
Baystate Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2016 and has held it in 13 quarters since.
Baystate Wealth Management's Alnylam Pharmaceuticals position peaked at $199K in Q3 2021.
499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.